Brain Cancer

Temporal Lobe Glioblastoma

Female, 70 years

Patient Internal 368807765

ICD-10 code

C71.2 Malignant Neoplasm of Temporal Lobe

Diagnosis (Incl. Metastases/Stage) and Year

November 2020
Glioblastoma of the Temporal Lobe, WHO IV, KI67 – up to 50%, IDH – wild type; MGMT – Methylated.

Previous Treatment

Radiation therapy, Chemotherapy (Temozolomide)

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of ~14 months from diagnosis.

Treatment Provided

Autologous DCV (6 doses) and CIK (4 doses) over a period of 5 months. Additionally, the patient received Xenogeneic Preventive and Therapeutic Anti-Cancer Vaccines (PTAC) (10 Vaccines).

Patient Survival/Condition and Year
Date of Review: 01/12/2023

The patient has survived for 30 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy and Radiation Therapy, has extended patient survival by an
estimate of around 16 months.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.

Ok